Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Krystexxa (pegloticase) is a recombinant uricase enzyme conjugated with polyethylene glycol (PEG), indicated for the treatment of chronic gout in adult patients who are refractory to conventional therapy. It converts uric acid into allantoin, a more water-soluble and easily excreted compound, thereby rapidly lowering serum uric acid levels. Krystexxa is typically reserved for severe, treatment-resistant cases of gout, particularly when patients are unable to tolerate or have not responded to xanthine oxidase inhibitors such as allopurinol or febuxostat. Its use is associated with a high risk of immunogenicity and infusion reactions, necessitating careful patient selection and monitoring.
| Fact Table | |
| Formula | Not applicable (pegylated recombinant enzyme) |
| License | US FDA (2010) |
| Bioavailability | Not applicable (IV only) |
| Legal status | Prescription only |
| Chemical Name | Pegloticase |
| Elimination half-life | ~10–12 days |
| Dosage (Strength) | 8 mg/1 mL solution (IV infusion every 2 weeks) |
| Pregnancy | Use only if clearly needed; limited human data |
| Brands | Krystexxa |
| Protein binding | Not applicable (enzyme therapy) |
| PubChem CID | 11509119 |
| MedlinePlus | a610019 |
| ChEBI | N/A |
| ATC code | M04AX02 |
| DrugBank | DB08868 |
| KEGG | D09750 |
| Routes of administration | Intravenous (IV) |
Krystexxa is administered via intravenous infusion at a dose of 8 mg every 2 weeks. Infusions should be given over at least 120 minutes in a healthcare setting equipped to manage anaphylaxis. Patients must be premedicated with antihistamines and corticosteroids before each infusion. Serum uric acid levels should be monitored prior to each dose; therapy should be discontinued if levels rise above 6 mg/dL on two consecutive measurements, as this may indicate loss of efficacy and increased risk of infusion reactions. Krystexxa is not for use in asymptomatic hyperuricemia.
Each single-dose vial contains:
Pegloticase 8 mg in 1 mL of solution (8 mg/mL)
Inactive ingredients include:
Disodium phosphate, monobasic sodium phosphate, sodium chloride, and water for injection
The solution is preservative-free and must be diluted in 0.9% sodium chloride prior to infusion. Do not shake.
Krystexxa is contraindicated in patients with:
Glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of hemolysis and methemoglobinemia
History of anaphylaxis or serious hypersensitivity reactions to pegloticase
Krystexxa carries a boxed warning for risk of anaphylaxis and infusion reactions. All patients should be screened for G6PD deficiency prior to initiation. Concomitant use of urate-lowering therapies (e.g., allopurinol, febuxostat) is contraindicated, as these can mask loss of pegloticase efficacy and increase the risk of infusion reactions. Discontinue therapy in patients who develop rising uric acid levels or severe adverse events. Use caution in patients with cardiovascular disease, as heart failure exacerbation has been reported.
Common and potential side effects include:
Infusion reactions (e.g., flushing, chest discomfort, hypotension)
Gout flares (particularly early in treatment)
Nausea
Bruising or urticaria
Anaphylaxis or delayed hypersensitivity
Rare: hemolysis or methemoglobinemia in G6PD-deficient patients
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews